Indication, Label, Approval, and Launch

Indication, label, approval, and launch are related but different concepts. They should not be collapsed into a single status field.

An indication describes the disease, condition, population, or use context for which a product is authorized or studied. A label is the official product information that defines approved use, dosing, safety information, contraindications, warnings, and other required details in a jurisdiction. An approval is a regulatory decision. A launch is a commercial event.

Terms that often get blended

Term	Practical meaning	Common misread
Studied indication	A use, condition, or population evaluated in a clinical program	Treating a trial target as an approved use
Labeled indication	A use authorized in the product label for a jurisdiction	Assuming the same indication applies in every country or product version
Approval	A regulatory decision allowing a product or label change under specified terms	Treating approval as proof of broad access, coverage, or supply
Label update	A change to official product information, such as a new indication or safety update	Treating all updates as new product approvals
Launch	A commercial introduction in a market	Assuming launch means stable availability or payer coverage
Availability	Whether a product can actually be obtained through relevant channels	Assuming availability is permanent or national without dated evidence
Coverage or reimbursement	Whether a payer or public system pays for a product under defined conditions	Treating payer access as identical to regulatory approval

These concepts can point in different directions. A product can be approved but not yet launched, launched but supply constrained, available in one market but not another, or covered only for specific populations under payer rules.

Why the distinction matters

Regulatory and market records change over time. A useful record needs to identify what kind of status is being described.

For database records, these details should be preserved when relevant:

date
jurisdiction
product
active ingredient
sponsor, applicant, or authorization holder
indication or label scope
population
status type
source
whether the record describes approval, label change, launch, coverage, shortage, supply, distribution, or availability

Without those fields, a phrase such as “approved,” “available,” or “covered” can become misleading.

Obesity-treatment examples

Event	Status type	Why scope matters
FDA approved Wegovy for chronic weight management in 2021	Initial US regulatory approval	The record concerns a specific product, ingredient, indication, jurisdiction, and date
FDA approved an added Wegovy indication in 2024 to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight	Label expansion or added indication	The cardiovascular-risk indication is not the same record as the original chronic weight-management approval
FDA approved Zepbound for long-term weight reduction and maintenance in a defined adult population in 2023	Initial US regulatory approval	The record connects tirzepatide, Zepbound, Eli Lilly, and the product-specific indication
FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity in 2024	Additional obesity-related indication	The sleep-apnea indication has its own population and label scope

These examples show why “approved” should usually be followed by date, jurisdiction, product, indication, and source.

Jurisdiction and timing

FDA approval, EMA assessment, European Commission authorization, and national market access decisions are not the same record. A product may have different labels, names, indications, launch timelines, authorization holders, reimbursement rules, or availability status across jurisdictions.

Timing also matters. Approval date, label-update date, launch date, shortage date, and coverage-policy date are separate milestones. They may occur months or years apart, and some may never occur in a given market.

Market access is a separate layer

Launch, coverage, reimbursement, pricing, distribution, and shortage status should be treated as market-access or availability records, not as automatic consequences of approval.

This matters because obesity-treatment products can be affected by payer restrictions, employer plans, public reimbursement rules, direct-to-consumer channels, pharmacy distribution, manufacturing capacity, and shortage notices. Those records are commercially important, but they are also time-sensitive and should carry dates and source context.

What not to infer

Approval does not automatically mean broad access. Label scope does not describe every real-world use. A studied indication is not necessarily an approved indication. Launch does not settle payer coverage, reimbursement, supply stability, or distribution. Availability in one jurisdiction does not establish availability elsewhere.

Regulatory and access pages should state the status type rather than relying on a single broad status label.